Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade
Executive Summary
Alnylam has outlined further data and analyses from the Phase III APOLLO study supporting the use of its selective interfering RNA agent, patisiran, as it nears the market for the treatment of hATTR amyloidosis.
You may also be interested in...
Alnylam CEO Maraganore To Step Aside At End Of 2021
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
Alnylam Switches Attention To Access After Onpattro EU Okay
European approval is in the bag for Onpattro for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis but in a week where ICER has criticized the price of the RNAi drug in the US, Alnylam now has to navigate reimbursement talks on this side of the Atlantic.
Alnylam's Onpattro Carries Narrower hATTR Indication Without Cardiac Data
US FDA still appears to be open, if not optimistic, about path towards broader label for patisiran, the first-of-its-kind targeted RNA-based therapy.